In patients with mental illness the increased risk from cardiovascular disease appears to be related to the increased incidence of obesity, hypertension, and diabetes mellitus. Barriers to the medical care in this patient population include diminished adherence to treatment and preventative recommendations, lack of willingness to engage in self-care activities, decreased access to affordable medical care, underestimation of risk by physicians, and adverse effects of commonly prescribed psychiatric medications. When managing patients with mental illness it is necessary to estimate the patient's metabolic and cardiovascular risk, monitor BMI, waist circumference, fasting glucose, and lipid profile regularly, evaluate psychiatric medications metabolic risk, and choose less “metabolically threatening” drugs. The promotion of healthy lifestyle choices among persons with serious mental illness is essential not only as part of their recovery, but as an integral part of preventing metabolic changes and weight gain linked to their illness and medication side effects. In patients with mental illness and co-morbid diabetes, metabolic syndrome, and obesity, psychiatrist and primary care clinicians should collaborate to establish a plan for healthy lifestyle habits (diet and activity regimen), encourage weight loss, and follow-up regularly using multispecialty teams to improve management.
FleischhackerWWCetkovich-BakmasMDe HertMHennekensCLambertMLeuchtS. Comorbid somatic illnesses in patients with severe mental disorders: Clinical, policy and research challenges. Journal of Clinical Psychiatry2008; 69: 514–519.
2.
CaseyDE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. American Journal of Medicine2005; 188(Suppl 2): 15S–22S.
3.
MillerBJPaschallCB3rdSvendsenDP. Mortality and medical comorbidity among patients with serious mental illness. Psychiatric Services2006; 57: 1482–1487.
4.
SusceMTVillanuevaNDiazFJde LeonJ. Obesity and associated complications in patients with severe mental illnesses: A cross-sectional survey. Journal of Clinical Psychiatry2005; 66: 167–173.
5.
JonesDRMacIasCBarreiraPJFisherWHHargreavesWAHardingCM. Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatric Services2004; 55: 1250–1257.
6.
HeiskanenTNiskanenLLyytikainenR. Metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychiatry2003; 64: 575–579.
7.
HeiskanenTHNiskanenLKHintikkaJJKoivumaa-HonkanenHTHonkalampiKMHaatainenKMViinamäkiHT. Metabolic syndrome and depression: A cross-sectional analysis. Journal of Clinical Psychiatry2006; 67(9): 1422–1427.
8.
FagioliniAFrankEScottJATurkinSKupferDJ. Metabolic syndrome in bipolar disorder: Findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disorders2005; 7(5): 424–430.
9.
GoffDCCatherCEvinsAE. Medical morbidity and mortality in schizophrenia: Guidelines for psychiatrists. Journal of Clinical Psychiatry2005; 66(2): 183–194.
10.
GuoJJKeckPEJrCorey-LislePK. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: A nested case-control study. Pharmacotherapy2007; 27(1): 27–35.
11.
American Diabetes Association: Consensus development conference on antipsychotic drugs and obesity and diabetes (Consensus Statement). Diabetes Care2004; 27: 596–601.
12.
Das-MunshiJStewartRIsmailKBebbingtonPEJenkinsRPrinceMJ. Diabetes, common mental disorders, and disability: Findings from the UK national psychiatry morbidity survey. Psychosomatic Medicine2007; 69: 543–550.
KiralyBGunningKLeiserJ. Primary care issues in patients with mental illness. American Family Physician2008; 78: 355–362.
15.
CrimsonMLArgoTRBuckleyPF. Schizophrenia. In: DiPiroJTTalbertRLYeeGCMatzkeGRWellsBGPoseyLM, editors, Pharmacotherapy: A pathophysiologic approach (7th ed.). New York: McGraw-Hill, 2008: 1099–1139.
16.
StahlSMMignonLMeyerJM. Which comes first: Atypical antipsychotic or cardio-metabolic risk?Acta Psychiatrica Scandinavica2009; 119: 171–179.
17.
NewcomerJW. Metabolic considerations in the use of antipsychotic medications. Journal of Clinical Psychiatry2007; 68(Suppl 1): 20–27.
18.
Alvarez-JiménezMGonzález-BlanchCVázquez-BarqueroJLPérezI. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: A randomized controlled trial. Journal of Clinical Psychiatry2006; 67(8): 1253–1260: S.n.
19.
AllisonDBMentoreJLHeoMChandlerLPCapelleriJCInfanteMC. Antipsychotic induced weight gain: Comprehensive research synthesis. American Journal of Psychiatry1999; 156: 1686–1696.
20.
KroezeWKHufeisenSJPopadakBA. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology2003; 28: 519–526: S.n.
21.
MuenchJHamerAM. Adverse effects of antipsychotic medications. American Family Physician2010; 81(5): 617–622.
22.
RamaswamyKKozmaCMNasrallahH. Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine. Drug Safety2007; 30(7): 589–599.
23.
RaederMBBjellandIVollsetSESteenVM. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: The Hordaland health study. Journal of Clinical Psychiatry2006; 67(12): 1974–1982.
24.
MainaGAlbertUSalviVBogettoF. Weight gain during long-term treatment of obsessive-compulsive disorder: A prospective comparison between serotonin reuptake inhibitors. Journal of Clinical Psychiatry2004; 65(10): 1365–1371.
25.
FavaM. Weight gain and antidepressants. Journal of Clinical Psychiatry2000; 61(Suppl 11): 37–41.
26.
Van Reedt DortlandAKGiltayEVan VeenTZitmanFGPenninxBW. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatrica Scandinavica2010; 122: 30–39.
27.
MartinCKHanHAntonSDGreenwayFLSmithSR. Effect of valproic acid on body weight, food intake, physical activity and hormones: Results of a randomized controlled trial. Journal of Psychopharmacology2009; 23(7): 814–825.
28.
BowdenCLCalabreseJRMcElroySLGyulaiLWassefAPettyF. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with 2-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Archives of General Psychiatry2000; 57: 481–489.
29.
SachsGBowdenCCalabreseJRKetterTThompsonTWhiteRBentleyB. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disorder2006; 8: 175–181.
30.
DeToledoJCToledoCDeCerceJRamsayRE. Changes in body weight with chronic, high-dose gabapentin therapy. Therapy Drug Monitoring1997; 19: 394–396.
31.
HoganREBertrandMEDeatonRLSommervilleKW. Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine and phenytoin. Epilepsy Research2000; 41: 23–28.
32.
DevinskyOVuongAHammerABarrettPS. Stable weight during lamotrigine therapy: A review of 32 studies. Neurology2000; 54: 973–975.
33.
HendersonDC. Atypical antipsychotic-induced diabetes mellitus: How strong is the evidence?CNS Drugs2002; 16: 77–89.
34.
LiebermanJA. Metabolic changes associated with antipsychotic use Primary Care Companion. Journal of Clinical Psychiatry2004; 6(Suppl 2): 8–13.
35.
American Dietetic Association. Adult weight management evidence based nutrition practice guidelines. Accessed September 18, 2010 from http://www.adaevidencelibrary.com
36.
American college of sports medicine position stand. Appropriate intervention strategies for weight loss and prevention of weight regain for adults. Medical Science Sports and Exercise2001; 33: 2145–2156.
37.
Executive Summary: Standards of medical care in diabetes—2010. Diabetes Care2010; 33: S4–S10.
38.
Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III. Accessed on October 28, 2010 from www.nhlbi.nih.gov/guidelines/cholesterol/index.htm
39.
National Institutes of Health, National Heart, Lung and Blood Institute. North American Association for the Study of Obesity. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. 2000. N 00–4084.
40.
SvetkeyLPStevensVJBrantleyPJ. Comparison of strategies for sustaining weight loss: The weight loss maintenance randomized controlled trial. Journal of the American Medical Association2008; 299: 1139–1148.
41.
SilversteinSMBellackAS. A scientific agenda for the concept of recovery as it applies to schizophrenia. Clinical Psychology Review2008; 28: 1108–1124.
42.
ComptonMTDaumitGLDrussBG. Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: A preventative perspective. Harvard Review of Psychiatry2006; 14: 212–222.
43.
CabassaLJEzellJMLewis-FernándezR. Lifestyle interventions for adults serious mental illness: A systematic literature review. Psychiatric Services2010; 61: 774–782.
44.
BusheCJBradleyAJ. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: Do the data inform as to potential guideline development? A systematic review of clinical studies. International Journal of Clinical Practice2009; 63(12): 1743–1761.
45.
WuRRZhaoJPGuoXF. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: A double-blind, placebo-controlled study. American Journal of Psychiatry2008; 165: 352–358.
46.
BaptistaTMartinezJLacruzA. Metformin for prevention of weight gain and insulin resistance with olanzapine: A double-blind placebo-controlled trial. Canadian Journal of Psychiatry2006; 51: 192–196.
47.
MaddiSFoxRHarveyRLuJKhoshabaDMPersicoM. Reduction in psychopathology following bariatric surgery for morbid obesity. Obesity Surgery2001; (11): 680–685.
48.
KoYHJoeSHJungIKKimSH. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. Clinical Neuropharmacology2005; 28: 169–175.
49.
BuchwaldHYoavABraunwaldEJensenMDPoriesWFahrbachK. Bariatric surgery: A systematic review and meta-analysis. Journal of the American Medical Association2004; 292: 1724–1737.
50.
DixonJBDixonMO'BrienPE. Pre-operative predictors of weight loss at 1-year after lap-band (R). Obesity Surgery2001; 11: 200–207.
51.
LehmanAFLiebermanJADixonLB., for the American Psychiatric Association Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia (2nd ed.). American Journal of Psychiatry2004; 161(2 Suppl): 1–56.
52.
MillerLevinson CDrussBGDombrowskiEARosen-HeckRA. Barriers to primary medical care among patients at a community mental health center. Psychiatric Services2003; 54(8): 1158–1160.
53.
ChafetzLWhiteMCCollins-BrideGNickensJCooperBA. Predictors of physical functioning among adults with severe mental illness. Psychiatric Services2006; 57(2): 225–231.
54.
Horvitz-LennonMKilbourneAMPincusHA. From silos to bridges: Meeting the general health care needs of adults with severe mental illnesses. Health Affairs2006; 25(3): 659–669.
55.
DrussBGVon EsenweinSAComptonMTRaskKJZhaoLParkerRMA. Randomized trial of medical care management for community mental health settings: The Primary Care Access, Referral, and Evaluation (PCARE) Study. American Journal of Psychiatry2010; 167: 151–159.
56.
GardnerDMBaldessariniRJWaraichP. Modern antipsychotic drugs: A critical overview. CMA Journal2005; 172(13): 1703–1711.
57.
FavaMJudgeRHoogSLNilssonMEKokeSC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: Changes in weight with long-term treatment. Journal of Clinical Psychiatry2000; 61(11): 863–867.
58.
HochstrasserBIsaksenPMKoponenHLauritzenLMahnertFARouillonF. Weight gain during long-term treatment of obsessive-compulsive disorder: A prospective comparison between serotonin reuptake inhibitors. British Journal of Psychiatry2001; 178: 304.
59.
CentorrinoFWurtmanJJDucaKAFellmanVHFogartyKVBerryJM. Weight loss in overweight patients maintained on atypical antipsychotic agents. International Journal of Obesity2006; 30: 1011–1016.
60.
MenzaMVreelandBMinskyS. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. Journal of Clinical Psychiatry2004; 65: 471–477.
61.
BrownCGoetzJVan SciverA. A psychiatric rehabilitation approach to weight loss. Psychiatric Rehabilitation Journal2006; 29: 267–273.
62.
BrarJSGanguliRPandinaG. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. Journal of Clinical Psychiatry2005; 66: 205–212.
63.
Jean-BaptisteMTekCLiskovE. A pilot study of a weight management program with food provision in schizophrenia. Schizophrenia Research2007; 96: 198–205.
64.
Van CittersADPrattSIJueK. A pilot evaluation of the In SHAPE individualized health promotion interventions for adults with mental illness. Community Mental Health Journal, December 10, 2009 [Epub ahead of print].
